Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

1 H-31 P magnetic resonance spectroscopy: effect of biotin in multiple sclerosis.

Guillevin C, Agius P, Naudin M, Herpe G, Ragot S, Maubeuge N, Philippe Neau J, Guillevin R.

Ann Clin Transl Neurol. 2019 Jul;6(7):1332-1337. doi: 10.1002/acn3.50825. Epub 2019 Jun 27.

2.

Analysis of a Mathematical Model for the Glutamate/Glutamine Cycle in the Brain.

Perrillat-Mercerot A, Bourmeyster N, Guillevin C, Miranville A, Guillevin R.

Bull Math Biol. 2019 Oct;81(10):4251-4270. doi: 10.1007/s11538-019-00647-4. Epub 2019 Jul 19.

PMID:
31325013
3.

Mathematical Modeling of Substrates Fluxes and Tumor Growth in the Brain.

Perrillat-Mercerot A, Bourmeyster N, Guillevin C, Miranville A, Guillevin R.

Acta Biotheor. 2019 Jun;67(2):149-175. doi: 10.1007/s10441-019-09343-1. Epub 2019 Mar 13.

PMID:
30868396
4.

Extent of Resection and Residual Tumor Thresholds for Postoperative Total Seizure Freedom in Epileptic Adult Patients Harboring a Supratentorial Diffuse Low-Grade Glioma.

Still MEH, Roux A, Huberfeld G, Bauchet L, Baron MH, Fontaine D, Blonski M, Mandonnet E, Guillevin R, Guyotat J, Taillandier L, Capelle L, Duffau H, Pallud J.

Neurosurgery. 2019 Aug 1;85(2):E332-E340. doi: 10.1093/neuros/nyy481.

PMID:
30395304
5.

Analysis of a mathematical model for brain lactate kinetics.

Guillevin C, Guillevin R, Miranville A, Perrillat-Mercerot A.

Math Biosci Eng. 2018 Oct 1;15(5):1225-1242. doi: 10.3934/mbe.2018056.

6.

Added Value of Spectroscopy to Perfusion MRI in the Differential Diagnostic Performance of Common Malignant Brain Tumors.

Vallée A, Guillevin C, Wager M, Delwail V, Guillevin R, Vallée JN.

AJNR Am J Neuroradiol. 2018 Aug;39(8):1423-1431. doi: 10.3174/ajnr.A5725. Epub 2018 Jul 26.

7.

Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging.

Freyschlag CF, Krieg SM, Kerschbaumer J, Pinggera D, Forster MT, Cordier D, Rossi M, Miceli G, Roux A, Reyes A, Sarubbo S, Smits A, Sierpowska J, Robe PA, Rutten GJ, Santarius T, Matys T, Zanello M, Almairac F, Mondot L, Jakola AS, Zetterling M, Rofes A, von Campe G, Guillevin R, Bagatto D, Lubrano V, Rapp M, Goodden J, De Witt Hamer PC, Pallud J, Bello L, Thomé C, Duffau H, Mandonnet E.

J Neurooncol. 2018 Sep;139(3):699-711. doi: 10.1007/s11060-018-2916-3. Epub 2018 Jul 10.

8.

High-Frequency Neuronavigated rTMS in Auditory Verbal Hallucinations: A Pilot Double-Blind Controlled Study in Patients With Schizophrenia.

Dollfus S, Jaafari N, Guillin O, Trojak B, Plaze M, Saba G, Nauczyciel C, Montagne Larmurier A, Chastan N, Meille V, Krebs MO, Ayache SS, Lefaucheur JP, Razafimandimby A, Leroux E, Morello R, Marie Batail J, Brazo P, Lafay N, Wassouf I, Harika-Germaneau G, Guillevin R, Guillevin C, Gerardin E, Rotharmel M, Crépon B, Gaillard R, Delmas C, Fouldrin G, Laurent G, Nathou C, Etard O.

Schizophr Bull. 2018 Apr 6;44(3):505-514. doi: 10.1093/schbul/sbx127.

9.

Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Int J Mol Sci. 2018 Apr 16;19(4). pii: E1212. doi: 10.3390/ijms19041212. Review.

10.

Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Neurosci Bull. 2018 Jun;34(3):573-588. doi: 10.1007/s12264-018-0219-5. Epub 2018 Mar 26. Review.

11.

Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Neuromolecular Med. 2018 Jun;20(2):174-204. doi: 10.1007/s12017-018-8486-x. Epub 2018 Mar 23. Review.

PMID:
29572723
12.

Aerobic glycolysis in amyotrophic lateral sclerosis and Huntington's disease.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Rev Neurosci. 2018 Jul 26;29(5):547-555. doi: 10.1515/revneuro-2017-0075. Review.

PMID:
29303786
13.

Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Oncotarget. 2017 Sep 23;8(52):90579-90604. doi: 10.18632/oncotarget.21234. eCollection 2017 Oct 27. Review.

14.

Reprogramming energetic metabolism in Alzheimer's disease.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Life Sci. 2018 Jan 15;193:141-152. doi: 10.1016/j.lfs.2017.10.033. Epub 2017 Oct 25. Review.

PMID:
29079469
15.

Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Acta Biochim Biophys Sin (Shanghai). 2017 Oct 1;49(10):853-866. doi: 10.1093/abbs/gmx073.

PMID:
28981597
16.

1H magnetic resonance spectroscopy suggests neural membrane alteration in specific regions involved in obsessive-compulsive disorder.

Hatchondo L, Jaafari N, Langbour N, Maillochaud S, Herpe G, Guillevin R, Guillevin C.

Psychiatry Res Neuroimaging. 2017 Nov 30;269:48-53. doi: 10.1016/j.pscychresns.2017.08.010. Epub 2017 Sep 14. No abstract available.

PMID:
28938221
17.

Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis.

Vallée A, Vallée JN, Guillevin R, Lecarpentier Y.

Cell Mol Neurobiol. 2018 May;38(4):783-795. doi: 10.1007/s10571-017-0550-9. Epub 2017 Sep 13. Review.

PMID:
28905149
18.

PPARγ agonists: Potential treatments for exudative age-related macular degeneration.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Life Sci. 2017 Nov 1;188:123-130. doi: 10.1016/j.lfs.2017.09.008. Epub 2017 Sep 6. Review.

PMID:
28887057
19.

Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/β-catenin pathway in gliomas.

Vallée A, Guillevin R, Vallée JN.

Rev Neurosci. 2018 Jan 26;29(1):71-91. doi: 10.1515/revneuro-2017-0032. Review.

PMID:
28822229
20.

Aerobic Glycolysis Hypothesis Through WNT/Beta-Catenin Pathway in Exudative Age-Related Macular Degeneration.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

J Mol Neurosci. 2017 Aug;62(3-4):368-379. doi: 10.1007/s12031-017-0947-4. Epub 2017 Jul 8. Review.

PMID:
28689265
21.

Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma.

Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.

Front Physiol. 2017 May 30;8:352. doi: 10.3389/fphys.2017.00352. eCollection 2017. Review.

22.

Preface.

Biermé H, Françoise JP, Guillevin R, Miranville A.

Acta Biotheor. 2016 Dec;64(4):309-310. Epub 2016 Oct 21. No abstract available.

PMID:
27770318
23.

Erratum to: Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I-III.

Desseroit MC, Visvikis D, Tixier F, Majdoub M, Perdrisot R, Guillevin R, Le Rest CC, Hatt M.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1933. No abstract available.

PMID:
27325234
24.

Exploration and Identification of Cortico-Cerebellar-Brainstem Closed Loop During a Motivational-Motor Task: an fMRI Study.

Belkhiria C, Driss T, Habas C, Jaafar H, Guillevin R, de Marco G.

Cerebellum. 2017 Apr;16(2):326-339. doi: 10.1007/s12311-016-0801-1.

PMID:
27271710
25.

Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III.

Desseroit MC, Visvikis D, Tixier F, Majdoub M, Perdrisot R, Guillevin R, Cheze Le Rest C, Hatt M.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1477-85. doi: 10.1007/s00259-016-3325-5. Epub 2016 Feb 20. Erratum in: Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1933.

26.

Neurological Manifestations in Parry-Romberg Syndrome: 2 Case Reports.

Vix J, Mathis S, Lacoste M, Guillevin R, Neau JP.

Medicine (Baltimore). 2015 Jul;94(28):e1147. doi: 10.1097/MD.0000000000001147.

27.

A framework using multimodal imaging for longitudinal monitoring of patients in neuro-oncology. Application to a SPECT/MRI study.

Tacchella JM, Yeni N, Roullot E, Lefort M, Cohen ME, Guillevin R, Petrirena G, Delattre JY, Habert MO, Kas A, Frouin F.

Conf Proc IEEE Eng Med Biol Soc. 2014;2014:1905-8. doi: 10.1109/EMBC.2014.6943983.

PMID:
25570351
28.

18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.

Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, Hindié E, Martineau A, Pradier O, Hustinx R, Perdrisot R, Guillevin R, El Naqa I, Visvikis D.

J Nucl Med. 2015 Jan;56(1):38-44. doi: 10.2967/jnumed.114.144055. Epub 2014 Dec 11.

29.

An efficient strategy based on an individualized selection of registration methods. Application to the coregistration of MR and SPECT images in neuro-oncology.

Tacchella JM, Roullot E, Lefort M, Cohen ME, Guillevin R, Petrirena G, Delattre JY, Habert MO, Yeni N, Kas A, Frouin F.

Phys Med Biol. 2014 Nov 21;59(22):6997-7011. doi: 10.1088/0031-9155/59/22/6997. Epub 2014 Oct 28.

PMID:
25350730
30.

Low-grade gliomas: the challenges of imaging.

Guillevin R, Herpe G, Verdier M, Guillevin C.

Diagn Interv Imaging. 2014 Oct;95(10):957-63. doi: 10.1016/j.diii.2014.07.005. Epub 2014 Sep 5. Review.

31.

Revisiting the spectrum of lower motor neuron diseases with snake eyes appearance on magnetic resonance imaging.

Lebouteux MV, Franques J, Guillevin R, Delmont E, Lenglet T, Bede P, Desnuelle C, Pouget J, Pascal-Mousselard H, Pradat PF.

Eur J Neurol. 2014 Sep;21(9):1233-41. doi: 10.1111/ene.12465. Epub 2014 May 22.

PMID:
24847978
32.

Epileptic seizures in diffuse low-grade gliomas in adults.

Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Párraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G.

Brain. 2014 Feb;137(Pt 2):449-62. doi: 10.1093/brain/awt345. Epub 2013 Dec 27.

PMID:
24374407
33.

A new strategy to improve coregistration of SPECT and MR images in patients with high grade glioma.

Tacchella JM, Roullot E, Lefort M, Cohen ME, Guillevin R, Petrirena G, Delattre JY, Habert MO, Yeni N, Kas A, Frouin F.

Conf Proc IEEE Eng Med Biol Soc. 2013;2013:4002-5. doi: 10.1109/EMBC.2013.6610422.

PMID:
24110609
34.

Central nervous system angiitis: a series of 31 patients.

Geri G, Saadoun D, Guillevin R, Crozier S, Lubetzki C, Mokhtari K, Amoura Z, Wechsler B, Le Boutin D, Costedoat-Chalumeau N, Samson Y, Cacoub P.

Clin Rheumatol. 2014 Jan;33(1):105-10. doi: 10.1007/s10067-013-2403-3. Epub 2013 Oct 6.

PMID:
24096639
35.

Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article.

Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H; French Réseau d'Étude des Gliomes.

J Neurosurg. 2013 Jun;118(6):1157-68. doi: 10.3171/2013.1.JNS121. Epub 2013 Mar 15.

PMID:
23495881
36.

Targeting accuracy of transcranial magnetic resonance-guided high-intensity focused ultrasound brain therapy: a fresh cadaver model.

Chauvet D, Marsac L, Pernot M, Boch AL, Guillevin R, Salameh N, Souris L, Darrasse L, Fink M, Tanter M, Aubry JF.

J Neurosurg. 2013 May;118(5):1046-52. doi: 10.3171/2013.1.JNS12559. Epub 2013 Mar 1.

PMID:
23451909
37.

Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.

Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N, Bauchet L, Peruzzi P, Frénay M, Colin P, Guillevin R, Bernier V, Baron MH, Guyotat J, Duffau H, Taillandier L, Capelle L.

Neuro Oncol. 2013 May;15(5):595-606. doi: 10.1093/neuonc/nos331. Epub 2013 Feb 7.

38.

On a minimal model for hemodynamics and metabolism of lactate: application to low grade glioma and therapeutic strategies.

Lahutte-Auboin M, Guillevin R, Françoise JP, Vallée JN, Costalat R.

Acta Biotheor. 2013 Mar;61(1):79-89. doi: 10.1007/s10441-013-9174-8. Epub 2013 Jan 20.

PMID:
23334287
39.

Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT.

Nioche C, Soret M, Gontier E, Lahutte M, Dutertre G, Dulou R, Capelle L, Guillevin R, Foehrenbach H, Buvat I.

Clin Nucl Med. 2013 Feb;38(2):81-7. doi: 10.1097/RLU.0b013e318279fd5a.

PMID:
23334119
40.

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.

Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, González-Aguilar A, Houillier C, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY.

Neuro Oncol. 2012 May;14(5):667-73. doi: 10.1093/neuonc/nos070. Epub 2012 Apr 4.

41.

Mathematical modeling of metabolism and hemodynamics.

Costalat R, Francoise JP, Menuel C, Lahutte M, Vallée JN, de Marco G, Chiras J, Guillevin R.

Acta Biotheor. 2012 Jun;60(1-2):99-107. doi: 10.1007/s10441-012-9157-1. Epub 2012 Mar 11.

42.

Proton MR spectroscopy in predicting the increase of perfusion MR imaging for WHO grade II gliomas.

Guillevin R, Menuel C, Abud L, Costalat R, Capelle L, Hoang-Xuan K, Habas C, Chiras J, Vallée JN.

J Magn Reson Imaging. 2012 Mar;35(3):543-50. doi: 10.1002/jmri.22862. Epub 2011 Nov 1.

PMID:
22045581
43.

[Multimodal magnetic resonance imaging of brain tumors].

Guillevin R, Menuel C, Vallée JN.

Rev Neurol (Paris). 2011 Oct;167(10):704-14. doi: 10.1016/j.neurol.2011.07.003. Epub 2011 Sep 7. Review. French.

PMID:
21903235
44.

[Delineation of glioblastoma, simplicity to complexity, the contribution of imaging].

Noël G, Guillevin R.

Cancer Radiother. 2011 Oct;15(6-7):484-94. doi: 10.1016/j.canrad.2011.07.237. Epub 2011 Aug 20. French.

PMID:
21862374
45.

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.

Guillevin R, Menuel C, Taillibert S, Capelle L, Costalat R, Abud L, Habas C, De Marco G, Hoang-Xuan K, Chiras J, Vallée JN.

Br J Cancer. 2011 Jun 7;104(12):1854-61. doi: 10.1038/bjc.2011.174. Epub 2011 May 24.

46.

[Medulloblastomas: review].

Taillandier L, Blonski M, Carrie C, Bernier V, Bonnetain F, Bourdeaut F, Thomas IC, Chastagner P, Dhermain F, Doz F, Frappaz D, Grill J, Guillevin R, Idbaih A, Jouvet A, Kerr C, Donadey FL, Padovani L, Pallud J, Sunyach MP.

Rev Neurol (Paris). 2011 May;167(5):431-48. doi: 10.1016/j.neurol.2011.01.014. Epub 2011 May 6. Review. French.

PMID:
21529869
47.

Mathematical modeling of energy metabolism and hemodynamics of WHO grade II gliomas using in vivo MR data.

Guillevin R, Menuel C, Vallée JN, Françoise JP, Capelle L, Habas C, De Marco G, Chiras J, Costalat R.

C R Biol. 2011 Jan;334(1):31-8. doi: 10.1016/j.crvi.2010.11.002. Epub 2010 Dec 28.

PMID:
21262484
48.

Natural history of incidental World Health Organization grade II gliomas.

Pallud J, Fontaine D, Duffau H, Mandonnet E, Sanai N, Taillandier L, Peruzzi P, Guillevin R, Bauchet L, Bernier V, Baron MH, Guyotat J, Capelle L.

Ann Neurol. 2010 Nov;68(5):727-33. doi: 10.1002/ana.22106.

PMID:
21031584
49.

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.

PMID:
20975057
50.

Functional connectivity of the superior human temporal sulcus in the brain resting state at 3T.

Habas C, Guillevin R, Abanou A.

Neuroradiology. 2011 Feb;53(2):129-40. doi: 10.1007/s00234-010-0775-5. Epub 2010 Oct 6.

PMID:
20924756

Supplemental Content

Loading ...
Support Center